Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infreshplus F is an ophthalmic solution containing carboxymethylcellulose sodium, developed and marketed by Taejoon Pharmaceutical for the treatment of dry eye syndrome. Carboxymethylcellulose is a high-molecular-weight cellulose derivative that functions as an ocular lubricant and surface protectant. It works by mimicking the mucin layer of the natural tear film, thereby increasing tear film stability and providing a protective barrier on the ocular surface. This action helps to alleviate symptoms such as dryness, irritation, and burning associated with tear deficiency or environmental factors. Infreshplus F is typically provided in single-use containers as a preservative-free formulation to minimize ocular surface irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylcellulose.